Odonate Therapeutics (ODT) Earning Somewhat Negative News Coverage, Study Shows

News coverage about Odonate Therapeutics (NASDAQ:ODT) has been trending somewhat negative recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Odonate Therapeutics earned a news impact score of -0.01 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.4194108451421 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of NASDAQ:ODT traded down $0.41 during trading hours on Monday, hitting $20.77. 8,546 shares of the company’s stock traded hands, compared to its average volume of 69,905. Odonate Therapeutics has a 1 year low of $15.15 and a 1 year high of $32.00. The firm has a market capitalization of $578.88 and a PE ratio of -8.97.

How to Become a New Pot Stock Millionaire

Odonate Therapeutics (NASDAQ:ODT) last announced its earnings results on Wednesday, February 14th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.14). analysts expect that Odonate Therapeutics will post -4.3 earnings per share for the current fiscal year.

Several research analysts recently commented on the company. Zacks Investment Research lowered Odonate Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. Goldman Sachs assumed coverage on Odonate Therapeutics in a research report on Tuesday, January 2nd. They set a “neutral” rating and a $27.00 target price for the company. Cowen assumed coverage on Odonate Therapeutics in a research report on Tuesday, January 2nd. They set an “outperform” rating for the company. Finally, Jefferies Group assumed coverage on Odonate Therapeutics in a research report on Tuesday, January 2nd. They set a “buy” rating and a $40.00 target price for the company.

In other news, CEO Kevin C. Tang purchased 128,255 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was purchased at an average price of $22.47 per share, for a total transaction of $2,881,889.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Boxer Capital, Llc purchased 100,000 shares of the stock in a transaction that occurred on Monday, March 26th. The stock was purchased at an average price of $22.73 per share, with a total value of $2,273,000.00. The disclosure for this purchase can be found here. Insiders have acquired 310,000 shares of company stock valued at $7,386,567 in the last 90 days.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by WKRB News and is the property of of WKRB News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.wkrb13.com/2018/04/02/odonate-therapeutics-odt-earning-somewhat-negative-news-coverage-study-shows.html.

About Odonate Therapeutics

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Insider Buying and Selling by Quarter for Odonate Therapeutics (NASDAQ:ODT)

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply